Ocugen (OCGN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$4.6M

Revenue (quarter)

$1.5M

Revenue growth (year over year)

+8.38%

Gross profit (trailing twelve months)

$4.6M

Gross margin

100.00%

Net income (trailing twelve months)

−$81.8M

Net income (quarter)

−$24.9M

Net income growth (year over year)

−68.78%

Net margin

−1785.88%

Return on equity

—

EPS (trailing twelve months)

−$0.26

Book value per share

−$0.05

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

113.33%

Payout ratio

—

Dividend yield

—

Company profile

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

• Is Ocugen (OCGN) profitable?

  No. Ocugen reported a net loss of $81.8M over the trailing twelve months.

• How much revenue does Ocugen (OCGN) make?

  Ocugen generated $4.6M in revenue over the trailing twelve months, up 8.38% year over year.

• How do I buy stock in Ocugen (OCGN)?

  OCGN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.